The repair tissue is the reason outcomes split

Two years after microfracture, a substantial proportion of patients who initially did well begin to lose ground — not because the surgery was performed poorly, but because the tissue it produces is the wrong kind.

Microfracture works by puncturing the subchondral bone plate to release mesenchymal stem cells from the marrow. Those cells migrate into the defect, form a clot, and differentiate into fibrochondrocytes — producing fibrocartilage composed predominantly of type I collagen. Type I collagen is the same protein found in scar tissue and tendons: strong in tension but poorly suited to the compressive and shear forces inside a weight-bearing joint.

Native articular cartilage is built on type II collagen, woven through a dense proteoglycan matrix that retains water under load, distributes stress evenly across the joint surface, and provides the low-friction glide that weight-bearing demands. Fibrocartilage cannot replicate this architecture. Under repetitive loading, it gradually erodes — a biological ceiling imposed by the pathway itself, not by any shortcoming in surgical technique.

ChondroFiller injection takes a different route entirely. By delivering a pre-formed injectable collagen scaffold into the defect without breaching the subchondral plate, it avoids triggering the marrow-stimulation cascade. Instead, the patient's own progenitor cells migrate into the scaffold structure, with the aim of building a repair matrix that more closely mirrors the mechanical properties of native cartilage.

Why microfracture results peak early then fall away

The survival data tells a precise story. Clinical scores and defect fill after microfracture typically peak somewhere between 12 and 24 months post-procedure — and then, for a significant proportion of patients, the trajectory reverses. Song et al. (2019, PMC6685863) found that between 47% and 80% of patients show measurable functional decline after that initial window closes, as the fibrocartilage repair tissue gradually yields under the repetitive compressive loading of daily movement.

Solheim et al. (2018, PMC6921956) quantified this pattern with survival analysis in a cohort of 203 patients followed for up to 18 years. Microfracture survival rates fell below 80% within 12 months of surgery and below 60% by three years. The mean time to failure was 4.0 years — compared with 8.4 years for osteochondral autograft transfer (OAT), a technique that transplants genuine hyaline cartilage rather than provoking the body to produce a fibrocartilage substitute. OAT survival remained above 80% at seven years. The overall long-term failure rate was 66% for microfracture versus 51% for OAT (P = 0.01). Ten-year follow-up data from Muthu et al. (2024) reinforces the same pattern, confirming that hyaline-preserving approaches consistently outperform marrow-stimulation techniques over time.

For most patients, microfracture offers a temporary repair rather than a durable one — which is why its use has been declining as longer-term evidence has accumulated.

Damage to the subchondral bone compounds the problem

The structural problem with microfracture failure extends well beyond symptom recurrence. When the fibrocartilage layer breaks down, the subchondral bone — which was intentionally perforated to initiate the repair — is exposed to the full compressive force of joint loading. Without a cartilage surface to distribute stress, the bone faces contact pressures it was not designed to bear alone.

The consequences can include subchondral cysts forming within unhealed bone cavities, localised bone remodelling, and accelerated osteoarthritis progression. Older patients and those with larger or multiple lesions carry a higher risk of this cascade; the repair tissue produced in those cases tends to be thinner and mechanically weaker from the outset.

What carries the most clinical weight here is how this structural deterioration affects future treatment. A subchondral plate that has been perforated and subsequently allowed to remodel under unshielded load provides a poor foundation for revision cartilage procedures. Prior marrow-stimulation surgery is associated with higher failure rates in subsequent cell-based approaches such as ACI and MACI — the altered bone architecture and residual scar tissue make a second attempt at durable repair considerably more demanding. In that sense, microfracture failure is not a neutral event: it can narrow the options available for restoring the joint at a later stage.

How ChondroFiller injection takes a structurally different route

ChondroFiller injection (Meidrix Biomedicals GmbH) is delivered as an ultrasound-guided outpatient procedure: a pre-formed injectable collagen scaffold is placed directly into the cartilage defect under image guidance, without penetrating the subchondral bone plate. There is no surgical theatre, no general anaesthesia, and no disruption to the bone architecture that supports the repair. The device carries CE marking as a Class III medical device.

In practical terms, this matters because the subchondral plate remains structurally intact throughout — providing a stable foundation for the regenerative process rather than becoming a site of secondary complications. The scaffold acts as a three-dimensional template into which the patient's own progenitor cells migrate and begin rebuilding cartilage matrix, a process known as matrix-induced chondrogenesis. Because no marrow stimulation is involved, the fibrocartilage pathway is not triggered.

The treatment is suited to focal defects up to approximately 3 cm², with the scaffold extendable to cover defects up to 6 cm² where the clinical picture supports it. It is applicable across multiple joints — knee, hip, ankle, shoulder, and several others — making it a versatile option in a way that many surgical cartilage techniques are not.

In current clinical use, reported outcomes include IKDC score improvements of approximately 30 points in the knee, a comparable mHHS gain of around 30 points in the hip, and MOCART scores in the range of 70–87, indicating meaningful defect fill on MRI assessment. These figures reflect the trajectory of scaffold-guided regeneration — they are reported outcomes from practice, not guarantees of individual results.

What the evidence actually shows — and where gaps remain

The microfracture evidence base is, by any reasonable standard, robust. Multiple peer-reviewed systematic reviews and cohort studies with follow-up extending beyond a decade consistently establish the same trajectory of early promise followed by progressive deterioration. Solheim et al. (2018) and Song et al. (2019) represent the kind of long-duration, hard-endpoint data that rarely requires qualification — the failure pattern they document has not been materially revised by subsequent re-analysis.

The picture for ChondroFiller injection at comparable timepoints is less settled. No direct head-to-head randomised controlled trial has yet compared ChondroFiller injection against microfracture at two- or three-year histological and functional endpoints in the peer-reviewed literature — partly because most of the microfracture long-term data predates the injectable scaffold pathway in its current clinical form. The mechanistic rationale for ChondroFiller injection — bypassing marrow stimulation, preserving the subchondral plate, avoiding the fibrocartilage pathway entirely — is well-grounded in cartilage biology, and reported clinical practice outcomes are encouraging. But mechanistic plausibility and clinical outcome data are different categories of evidence, and conflating them does not serve patients well.

What that asymmetry means in practice: the case for ChondroFiller injection is coherent and growing, but independent comparative trial validation would move it from well-reasoned to established. For patients whose lesion size or profile makes more than one approach technically viable, that distinction is the most useful thing to take into a specialist assessment.

Which patients are realistic candidates for each approach

Practical eligibility hinges on four overlapping factors: lesion size, patient age, the joint affected, and prior treatment history.

Microfracture is generally considered appropriate only for younger patients with small, isolated focal defects — historically under 2 cm² — and current evidence does not support it as a modern first-line choice for most presentations. Older patients and those with larger or multiple lesions carry substantially higher risk of osteoarthritis progression. The procedure also narrows future options: prior marrow stimulation can complicate or preclude subsequent repair, making revision planning an important conversation for anyone with a microfracture history.

ChondroFiller injection covers the focal defect size range described earlier in this article, across a wide range of joints. It is particularly relevant where outpatient management is preferred or where surgical candidacy is limited — factors that often coincide in practice.

For larger defects, diffuse osteoarthritis, or cases where prior procedures have failed, techniques such as MACI, ACI, osteochondral autograft transfer, or fresh osteochondral allograft remain relevant pathways, each with a distinct risk-benefit profile that a full assessment will weigh.

No single criterion determines the right pathway in isolation. A specialist cartilage assessment will consider lesion grade (Outerbridge/ICRS), defect dimensions, joint loading demands, age, and prior treatment history together — and patients considering their options are welcome to arrange that assessment at the London Cartilage Clinic.